Abstract: Compounds, compositions and methods are provided for modulating the expression of selenoprotein W. The compositions comprise oligonucleotides, targeted to nucleic acid encoding selenoprotein W. Methods of using these compounds for modulation of selenoprotein W expression and for diagnosis and treatment of disease associated with expression of selenoprotein W are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of BCL2-associated athanogene. The compositions comprise oligonucleotides, targeted to nucleic acid encoding BCL2-associated athanogene. Methods of using these compounds for modulation of BCL2-associated athanogene expression and for diagnosis and treatment of disease associated with expression of BCL2-associated athanogene are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of CGG triplet repeat binding protein 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CGG triplet repeat binding protein 1. Methods of using these compounds for modulation of CGG triplet repeat binding protein 1 expression and for diagnosis and treatment of disease associated with expression of CGG triplet repeat binding protein 1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of UBE2G1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding UBE2G1. Methods of using these compounds for modulation of UBE2G1 expression and for diagnosis and treatment of disease associated with expression of UBE2G1 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of fibrillarin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding fibrillarin. Methods of using these compounds for modulation of fibrillarin expression and for diagnosis and treatment of disease associated with expression of fibrillarin are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of jumonji. The compositions comprise oligonucleotides, targeted to nucleic acid encoding jumonji. Methods of using these compounds for modulation of jumonji expression and for diagnosis and treatment of disease associated with expression of jumonji are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of ADAM9. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ADAM9. Methods of using these compounds for modulation of ADAM9 expression and for diagnosis and treatment of disease associated with expression of ADAM9 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of mitogen-activated protein kinase kinase kinase 11. The compositions comprise oligonucleotides, targeted to nucleic acid encoding mitogen-activated protein kinase kinase kinase 11. Methods of using these compounds for modulation of mitogen-activated protein kinase kinase kinase 11 expression and for diagnosis and treatment of disease associated with expression of mitogen-activated protein kinase kinase kinase 11 are provided.

Abstract: Compounds, compositions and methods are provided for modulating the expression of endothelial differentiation gene 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial differentiation gene 2. Methods of using these compounds for modulation of endothelial differentiation gene 2 expression and for diagnosis and treatment of disease associated with expression of endothelial differentiation gene 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.

Abstract: Compositions and methods are provided for inhibiting the expression of TGF-&bgr;2. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TGF-&bgr;2 are preferred. Methods of using these compounds for modulation of TGF-&bgr;2 expression and for treatment of diseases associated with expression of TGF-&bgr; are also provided.

Abstract: Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.

Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPP3CB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP3CB. Methods of using these compounds for modulation of PPP3CB expression and for treatment of diseases associated with expression of PPP3CB are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PPP2R1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP2R1A. Methods of using these compounds for modulation of PPP2R1A expression and for treatment of diseases associated with expression of PPP2R1A are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cyclin-dependent kinase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cyclin-dependent kinase 4. Methods of using these compounds for modulation of cyclin-dependent kinase 4 expression and for treatment of diseases associated with expression of cyclin-dependent kinase 4 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cell division cycle 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cell division cycle 2. Methods of using these compounds for modulation of cell division cycle 2 expression and for treatment of diseases associated with expression of cell division cycle 2 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of geranylgeranyl diphosphate synthase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding geranylgeranyl diphosphate synthase 1. Methods of using these compounds for modulation of geranylgeranyl diphosphate synthase 1 expression and for treatment of diseases associated with expression of geranylgeranyl diphosphate synthase 1 are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of HMG-CoA reductase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding HMG-CoA reductase. Methods of using these compounds for modulation of HMG-CoA reductase expression and for treatment of diseases associated with expression of HMG-CoA reductase are provided.